Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDS 2020 | Erythropoiesis-stimulating agents in MDS

Valeria Santini • 17 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Valeria Santini, MD, University of Florence, Florence, Italy, outlines the impact of different doses of erythropoiesis-stimulating agents in patients with myelodysplastic syndromes (MDS) in an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Valeria Santini

Key debates in MDS at ASH 2025: diagnosis, pre-disease therapy, & more
2:53
Key debates in MDS at ASH 2025: diagnosis, pre-disease therapy, & more
Valeria Santini • 5 Dec 2025
Long-term survival results from COMMANDS: luspatercept versus EPO in LR-MDS
2:30
Long-term survival results from COMMANDS: luspatercept versus EPO in LR-MDS
Valeria Santini • 5 Dec 2025
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS
2:26
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS
Valeria Santini • 5 Dec 2025
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
7:55
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
Valeria Santini • 5 Sep 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Valeria Santini • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Valeria Santini • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Valeria Santini • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Valeria Santini • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals